Hansen Pharmaceutical Group Limited (the "Company") announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company and its subsidiaries (collectively the "Group") achieved revenue of approximately RMB 6.506 billion, a year-on-year increase of approximately 44.2%; revenue from innovative drugs and partnership products was approximately RMB 5.032 billion, a year-on-year increase of approximately 80.6%, accounting for approximately 77.4% of total revenue; research and development expenses were approximately RMB 1.196 billion, a year-on-year increase of approximately 28.7%, accounting for approximately 18.4% of total revenue; net profit was approximately RMB 2.726 billion, a year-on-year increase of approximately 111.5%; basic earnings per share were approximately RMB 0.46, a year-on-year increase of approximately 111.4%. The increase in revenue, net profit, and...Show More

Hansen Pharmaceutical Group Limited (the "Company") announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company and its subsidiaries (collectively the "Group") achieved revenue of approximately RMB 6.506 billion, a year-on-year increase of approximately 44.2%; revenue from innovative drugs and partnership products was approximately RMB 5.032 billion, a year-on-year increase of approximately 80.6%, accounting for approximately 77.4% of total revenue; research and development expenses were approximately RMB 1.196 billion, a year-on-year increase of approximately 28.7%, accounting for approximately 18.4% of total revenue; net profit was approximately RMB 2.726 billion, a year-on-year increase of approximately 111.5%; basic earnings per share were approximately RMB 0.46, a year-on-year increase of approximately 111.4%. The increase in revenue, net profit, and basic earnings per share during the period was mainly due to the increase in revenue from innovative drugs and partnership products. The Company continues to innovate and is committed to becoming a leading global innovative pharmaceutical company. As of the end of the reporting period, the Group has obtained market approval for seven innovative drugs, all of which have been included in the "National Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List" ("National Insurance Drug List") published by the National Healthcare Security Administration ("NHSA") of China. The Company continuously improves its environmental, social, and governance (ESG) practices and has been selected for the "Sustainable Development Yearbook (Chinese Edition) 2024" published by S&P Global, ranking among the top 1% in the industry for ESG scores.